Your activity: 38 p.v.
< Back
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Recommended and minimum ages and intervals between vaccine doses*Δ

Recommended and minimum ages and intervals between vaccine doses*Δ
Vaccine and dose number Recommended age for this dose Minimum age for this dose Recommended interval through next dose Minimum interval through next dose
Diphtheria and tetanus toxoids and acellular pertussis (DTaP)
DTaP-1◊ 2 months 6 weeks 8 weeks 4 weeks
DTaP-2 4 months 10 weeks 8 weeks 4 weeks
DTaP-3 6 months 14 weeks 6 through 12 months§ 6 months§
DTaP-4 15 through 18 months 15 months§ 3 years 6 months
DTaP-5 4 through 6 years 4 years – –
Hepatitis A (HepA)
HepA-1◊ 12 through 23 months 12 months 6 through 18 months 6 months
HepA-2 ≥18 months 18 months – –
Hepatitis B (HepB)
HepB-1 Birth Birth 4 weeks through 4 months 4 weeks
HepB-2 1 through 2 months 4 weeks 8 weeks through 17 months 8 weeks
HepB-3¥ 6 through 18 months 24 weeks – –
Haemophilus influenzae type b (Hib)
Hib-1◊‡ 2 months 6 weeks 8 weeks 4 weeks
Hib-2 4 months 10 weeks 8 weeks 4 weeks
Hib-3† 6 months 14 weeks 6 through 9 months 8 weeks
Hib-4 12 through 15 months 12 months – –
Human papillomavirus (HPV)
HPV-1** 11 through 12 years 9 years 8 weeks 4 weeks
HPV-2 11 through 12 years
(+2 months)		 9 years
(+4 weeks)		 4 months 12 weeks**
HPV-3**,¶¶ 11 through 12 years
(+6 months)		 9 years
(+5 months)		 – –
Herpes zoster vaccine (HZV)
HZVΔΔ ≥60 years 60 years – –
Inactivated influenza vaccine (IIV)
IIV◊◊ ≥6 months 6 months§§ 4 weeks 4 weeks
Inactivated poliovirus (IPV)
IPV-1◊ 2 months 6 weeks 8 weeks 4 weeks
IPV-2 4 months 10 weeks 8 weeks through 14 months 4 weeks
IPV-3 6 through 18 months 14 weeks 3 through 5 years 6 months
IPV-4¥¥ 4 through 6 years 4 years – –
Live, attenuated influenza vaccine (LAIV)
LAIV (intranasal)◊◊ 2 through 49 years 2 years 4 weeks 4 weeks
Quadrivalent meningococcal conjugate vaccine (MenACWY)
MenACWY-1‡‡ 11 through 12 years 6 weeks†† 4 through 5 years 8 weeks
MenACWY-2 16 years 11 years
(+8 weeks)***		 – –
Measles, mumps, and rubella (MMR)
MMR-1¶¶¶ 12 through 15 months 12 months 3 through 5 years 4 weeks
MMR-2¶¶¶ 4 through 6 years 13 months – –
Quadrivalent meningococcal polysaccharide vaccine (MPSV4)
MPSV4-1‡‡ – 2 years 5 years 5 years
MPSV4-2 – 7 years – –
Pneumococcal conjugate vaccine (PCV13)
PCV13-1‡ 2 months 6 weeks 8 weeks 4 weeks
PCV13-2 4 months 10 weeks 8 weeks 4 weeks
PCV13-3 6 months 14 weeks 6 months 8 weeks
PCV13-4 12 through 15 months 12 months – –
Pneumococcal polysaccharide vaccine (PPSV23)
PPSV23-1 – 2 years 5 years 3 years
PPSV23-2ΔΔΔ – 7 years – –
Rotavirus
Rotavirus-1◊◊◊ 2 months 6 weeks 8 weeks 4 weeks
Rotavirus-2 4 months 10 weeks 8 weeks 4 weeks
Rotavirus-3◊◊◊ 6 months 14 weeks – –
Tetanus and diphtheria toxoids (Td)
Td 11 through 12 years 7 years 10 years 5 years
Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap)
Tdap§§§ ≥11 years 7 years – –
Varicella vaccine (VAR)
VAR-1 12 through 15 months 12 months 3 through 5 years 12 weeks¥¥¥
VAR-2 4 through 6 years 15 months‡‡‡ – –
PRP-OMP: polyribosylribitol phosphate-meningococcal outer membrane protein conjugate.
* Combination vaccines are available. Use of licensed combination vaccines is generally preferred to separate injections of their equivalent component vaccines. When administering combination vaccines, the minimum age for administration is the oldest age for any of the individual components (exception: the minimum age for the first dose of MenHibrix is 6 weeks). The minimum interval between doses is equal through the greatest interval of any of the individual components.
¶ Information on travel vaccines, including typhoid, Japanese encephalitis, and yellow fever can be found at https://wwwnc.cdc.gov/travel/. Information on other vaccines that are licensed in the United States but not distributed, including anthrax and smallpox can be found at https://emergency.cdc.gov/bioterrorism/.
Δ "Months" refers through calendar months.
◊ Combination vaccines containing the hepatitis B component are available (refer to Table 3-2 available at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html#t-02). These vaccines should not be administered to infants aged <6 weeks because of the other vaccine components (ie, Hib, DTaP, HepA, and IPV).
§ The minimum recommended interval between DTaP-3 and DTaP-4 is 6 months. However, DTaP-4 need not be repeated if administered at least 4 months after DTaP-3. This is a special grace period of 2 months which can be used if evaluating records retrospectively. An additional 4 days should not be added to this grace period.
¥ HepB-3 should be administered at least 8 weeks after HepB-2 and at least 16 weeks after HepB-1 and should not be administered before age 24 weeks.
‡ For Hib and PCV13, children receiving the first dose of vaccine at age ≥7 months require fewer doses to complete the series.
† If PRP-OMP (Pedvax-Hib) was administered at ages 2 and 4 months, a dose at age 6 months is not necessary. The final dose has a minimum age of 12 months.
** Quadrivalent and nine-valent HPV vaccines are approved for males and females aged 9 through 26 years. The minimum age for HPV-3 is based on the baseline minimum age for the first dose (ie, 9 years) and the minimum interval of 5 months between the first and third dose. Dose 3 need not be repeated if it is administered at least 5 months after the first dose and the intervals between dose 1 and dose 2, and dose 2 and dose 3, are maintained at 4 weeks and 12 weeks, respectively.
¶¶ A two-dose schedule of HPV vaccine is recommended for most persons beginning the series between 9 through 14 years of age. Refer to "HPV vaccine-specific recommendations" (available at https://www.cdc.gov/mmwr/volumes/65/wr/pdfs/mm6549a5.pdf) for details.
ΔΔ Herpes zoster vaccine is recommended as a single dose for persons aged ≥60 years.
◊◊ One dose of influenza vaccine per season is recommended for most persons. To determine which children younger than 9 years should receive 2 doses in a single season, please refer to influenza vaccine-specific recommendations.[1]
§§ The minimum age for inactivated influenza vaccine varies by vaccine manufacturer. Refer to the package insert for vaccine-specific minimum ages.
¥¥ A fourth dose is not needed if the third dose was administered at ≥4 years and at least 6 months after the previous dose.
‡‡ Revaccination with meningococcal vaccine is recommended for previously vaccinated persons who remain at high-risk for meningococcal disease.[2]
†† MenACWY-D (Menactra) can be given as young as 9 months for high-risk persons. MenACWY-CRM (Menveo) can be given as young as 2 months for high-risk persons. Hib-MenCY can be given as young as 6 weeks for high-risk persons. Hib-MenCY is given as a 4-dose series at 2 months, 4 months, 6 months, and 12 through 18 months.
*** For routine non-high-risk adolescent vaccination, the minimum age for the booster dose is 16 years.
¶¶¶ Combination MMRV vaccine can be used for children aged 12 months through 12 years.
ΔΔΔ A second dose of PPSV23 5 years after the first dose is recommended for persons aged ≤65 years at highest risk for serious pneumococcal infection and those who are likely to have a rapid decline in pneumococcal antibody concentration.[3]
◊◊◊ The first dose of rotavirus must be administered at age 6 weeks through 14 weeks, 6 days. The vaccine series should not be started for infants aged ≥15 weeks, 0 days. Rotavirus should not be administered to children older than 8 months, 0 days of age regardless of the number of doses received between 6 weeks and 8 months, 0 days of age. If 2 doses of Rotarix are administered as age appropriate, a third dose is not necessary.
§§§ Only 1 dose of Tdap is recommended. Subsequent doses should be given as Td. For management of a tetanus-prone wound in persons who have received a primary series of tetanus-toxoid-containing vaccine, the minimum interval after a previous dose of any tetanus-containing vaccine is 5 years.
¥¥¥ A special grace period of 2 months, based on expert opinion, can be applied to the minimum interval of 3 months, when evaluating records retrospectively, which results in an acceptable minimum interval of 4 weeks. An additional 4 days should not be added on through this grace period.
‡‡‡ A special grace period of 2 months, based on expert opinion, can be applied to the minimum age of 15 months when evaluating records retrospectively, which results in an acceptable minimum age of 13 months. An additional 4 days should not be added on through this grace period.
References:
  1. Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2014-15 influenza season. MMWR Morb Mortal Wkly Rep 2014; 63:691.
  2. Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1.
  3. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46:1.
Reproduced from: Centers for Disease Control and Prevention. Vaccine Recommendations and Guidelines of the ACIP: Timing and Spacing of Immunobiologics. Available at: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html (Accessed July 7, 2017).
Graphic 68034 Version 6.0